FDA approves Biotronik’s programmer for implanted cardiac rhythm management devices

Biotronik announced today that the FDA approved its Renamic Neo programmer for implanted cardiac rhythm management devices.

Lake Oswego, Oregon-based Biotronik designed its Renamic Neo programmer for implanted devices, including ICDs, pacemakers and implantable cardiac monitors.

According to a news release, Renamic Neo offers LifeSupport for clinicians to share the programmer screen with or grant programmer control to Biotronik technical support personnel at remote locations. It has compatibility with Biotronik’s ReportShare and EHR DataSync to allow for the secure and easy integration of programmer data into hospitals’ EHR systems.

Renamic Neo also has a 12-in., high-resolution, high-contrast LCD touch screen display, a built-in analyzer and battery-powered portability. The company said the system is also significantly lighter and smaller than the previous iteration. Biotronik will make the platform available in the U.S. soon, it said.

“The Renamic Neo programmer represents another advancement in providing clinicians with better tools to improve patient care,” Westchester Medical Health Network (Valhalla, New York) Section Chief for Cardiac Electrophysiology Dr. Sei Iwai said in the release. “The LiveSupport feature, ReportShare, and EHR DataSync, plus all the connectivity options in this programmer, can improve our workflow and response time. The Renamic Neo programmer is exactly the tool we need in our device clinic.”

Original Article: (https://www.medicaldesignandoutsourcing.com/fda-approves-biotroniks-programmer-for-implanted-cardiac-rhythm-management-devices/)